SCHEMBL4194840

SCHEMBL4194840

CC(CC1CCCCC1)NCc1ncccc1NC(=O)O

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPY5R Q15761 1/20 0.38
KDM4E B2RXH2 1/20 0.38
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37
HPGD P15428 2/20 0.37
NPSR1 Q6W5P4 2/20 0.37
RECQL P46063 1/20 0.37
GCK P35557 2/20 0.37
CNR1 P21554 1/20 0.37
CNR2 P34972 1/20 0.37
P2RX7 Q99572 1/20 0.36
ALDH1A1 P00352 1/20 0.36
NPC1 O15118 1/20 0.35
TP53 P04637 1/20 0.35
TSHR P16473 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
KCNQ3 O43525 1/20 0.35
KCNQ2 O43526 1/20 0.35
GPR132 Q9UNW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4190351 0.82 MME (0.40) NPY5RKDM4EMEN1KMT2AHPGD
SCHEMBL4192548 0.81 KMT2A (0.47) NPY5RKDM4EMEN1KMT2AHPGD
SCHEMBL4707353 0.80 CNR1 (0.36) NPY5RKDM4EMEN1KMT2AHPGD
SCHEMBL4194046 0.80 HTR1A (0.36) KDM4EMEN1KMT2AHPGDRECQL
SCHEMBL4197451 0.78 KDM4C (0.42) NPY5RCNR1CNR2SMN1; SMN2F2RL1
SCHEMBL4190519 0.78 KDM4C (0.45) NPY5RCNR1
SCHEMBL4707118 0.78 KDM4E (0.40) KDM4EMEN1KMT2AHPGDNPSR1
SCHEMBL4192695 0.76 NFKBIA (0.46) KDM4EMEN1KMT2ANPSR1ALDH1A1
SCHEMBL4189874 0.75 KDM4E (0.43) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL4187962 0.72 KDM4E (0.36) KDM4EMEN1KMT2AHPGDNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP claimed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US claimed
EP-1879877-B1 ANTIMICROBIAL AGENTS RANBAXY LAB LTD (IN) 2013-01-02 EP disclosed
US-8076370-B2 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2011-12-13 US disclosed
US-20090215764-A1 Antimicrobial agents RANBAXY LABORATORIES LIMITED (IN) 2009-08-27 US disclosed
EP-1879877-A2 ANTIMICROBIAL AGENTS Ranbaxy Laboratories Limited (IN) 2008-01-23 EP disclosed
WO-2006117762-A2 ANTIMICROBIAL AGENTS RANBAXY LABORATORIES LIMITED (IN) 2006-11-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215764-A1 Antimicrobial agents TUFM, RPS17, HARS1 NPY5R 4715/4885KDM4E 3328/4885MEN1 3776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.